 SAN DIEGO, Aug. 24, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento today announced that it has entered into an option agreement Option with The Texas AM University System TAMUS for exclusive rights to the intellectual property covering highly potent main protease MPro inhibitors against SARS-CoV-2. This latest agreement bolsters Sorrentos wide-ranging portfolio of preclinical and clinical therapeutic candidates targeting COVID-19, including new and emerging variants of concern of the SARS-CoV-2 virus. Under the terms of the agreement, Sorrento has an exclusive option to exclusively license patents covering the MPro inhibitor drug candidates. 